Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA3 | P07451 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7629070 | 0.82 | SMN1; SMN2 (0.80) | SMN1; SMN2GAACA2CA1CA12 | |
| SCHEMBL521508 | 0.79 | L3MBTL1 (0.49) | ENPP2SMN1; SMN2GAACA2CA1 | |
| SCHEMBL2323303 | 0.79 | ENPP2 (0.55) | ENPP2SMN1; SMN2CA2CA1CA12 | |
| SCHEMBL29952899 | 0.79 | L3MBTL1 (0.49) | ENPP2SMN1; SMN2GAACA2CA1 | |
| SCHEMBL16277617 | 0.79 | SMN1; SMN2 (0.62) | ENPP2SMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL387619 | 0.79 | ENPP2 (0.55) | ENPP2GAACA2CA1CA12 | |
| SCHEMBL3915021 | 0.79 | ALDH1A1 (0.61) | ENPP2CA2CA1CA12CA9 | |
| SCHEMBL29950584 | 0.78 | ALDH1A1 (0.66) | ENPP2SMN1; SMN2CA2CA1CA12 | |
| SCHEMBL7926321 | 0.76 | CA12 (0.62) | ENPP2SMN1; SMN2GAACA2CA1 | |
| SCHEMBL7020553 | 0.76 | SMN1; SMN2 (0.64) | ENPP2SMN1; SMN2GAACA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210790-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | THE JOHNS HOPKINS UNIVERSTY | 2023-07-06 | — | — | US | claimed |
| EP-4157998-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | The Johns Hopkins University (US) | 2023-04-05 | — | — | EP | claimed |
| EP-3344232-B1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | UNIV MCMASTER (CA) | 2022-01-26 | — | — | EP | claimed |
| US-10611908-B2 | Micelles for mucoadhesive drug delivery | MCMASTER UNIVERSITY (CA) | 2020-04-07 | — | — | US | claimed |
| US-20180265694-A1 | Micelles for Mucoadhesive Drug Delivery | MCMASTER UNIVERSITY (CA) | 2018-09-20 | — | — | US | claimed |
| EP-3344232-A1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | Mcmaster University (CA) | 2018-07-11 | — | — | EP | claimed |
| WO-2017035656-A1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | MCMASTER UNIVERSITY (CA) | 2017-03-09 | — | — | WO | claimed |
| EP-4743081-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| WO-2025019407-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| EP-3746437-B1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-08-21 | — | — | EP | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-04-11 | — | — | US | disclosed |
| WO-2008052733-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| WO-2007056341-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | ENPP2 420/4885SMN1; SMN2 4663/4885GAA 3040/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | ENPP2 522/4885SMN1; SMN2 1949/4885GAA 3882/4885 |
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAP3K4, MAP4K1 | ENPP2 2168/4885SMN1; SMN2 2354/4885GAA 4535/4885 |
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | ENPP2 13/4885SMN1; SMN2 3867/4885GAA 2559/4885 |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | ENPP2 2168/4885SMN1; SMN2 2354/4885GAA 4535/4885 |
| US-20230210790-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | EPX, EPCAM, ELANE | ENPP2 128/4885SMN1; SMN2 3198/4885GAA 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.